SciELO - Scientific Electronic Library Online

 
vol.7 suppl.2Colombian Expert Consensus on Evidence-Informed Recommendations for the Prevention, Diagnosis, and Management of SARS-CoV-2 / COVID-19 Infection in Patients with Chronic Kidney Disease on DialysisCOVID-19. Therapeutics options from the viro-pathogenesis to the clinical evidence author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista Colombiana de Nefrología

On-line version ISSN 2500-5006

Abstract

YOMAYUSA GONZALEZ, Nancy et al. Use of evidence summaries to inform pharmacological treatment of people with suspected or diagnosedSARS-CoV-2/COVID-19 respiratory infection. Rev. colom. nefrol. [online]. 2020, vol.7, suppl.2, pp.160-182.  Epub May 12, 2021. ISSN 2500-5006.  https://doi.org/10.22265/acnef.7.supl.2.407.

Introduction:

Due to the emergence of the SARS-CoV-2 coronavirus since December 2019, a large volume of scientific production has been generated, in some cases uncertain or controversial, especially in the pharmacological management of patients with this infection; therefore, it is considered a relevant search for methodological alternatives to carry out its rigorous, systematic and quality synthesis, but with less execution time and lower cost.

Objective:

To present the available evidence regarding the pharmacological management of people with suspected or diagnosed respiratory SARS-CoV-2 (COVID-19) using the method of rapid systematic reviews (RS-R) in potentially effective drugs for their management.

Methodology:

A systematic and structured search was conducted in Medline, Embase, Scopus, Cochrane Library, Clinical trials and Google Scholar in English. Studies included clinical practice guidelines, consensus, systematic reviews, meta-analyses, clinical trials, and other primary studies. Data search and extraction were performed by multiple reviewers, but none were paired.

Results:

Sixteen questions of clinical interest were resolved, related to the use in COVID-19 of lopinavir/ritonavir, nelfinavir, oseltamivir, remdesivir, ribavirin, teicoplanin, umifenovir, favipiravir, tocilizumab, ivermectin, convalescent plasma; the use of support management drugs such as dexamethasone were also evaluated, as well as the concomitant use of drugs that generated doubts, such as NSAIDs, ACEis, and ARA IIs.

Conclusions:

Summaries of evidence are within the pandemic scenario as a good methodological alternative to offer quality information in the short term for decision-makers.

Keywords : COVID-19; severe acute respiratory syndrome coronavirus 2; drug therapy; antivirals agents; SARS-CoV-2.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )